Mannitol is the standard of care for patients with increased intracranial pressure (ICP), but multiple administrations of mannitol risk renal toxicity and fluid accumulation in the brain parenchyma with consequent worsening of cerebral edema. This preliminary study assessed the safety and efficacy of small-volume injections of 23.4% sodium chloride solution for the treatment of intracranial hypertension in patients with traumatic brain injury who became tolerant to mannitol. METHODS: We retrospectively reviewed the charts of 13 adult patients with traumatic brain injury who received mannitol and 23.4% sodium chloride independently for the treatment of intracranial hypertension at San Francisco General Hospital between January and October 2003. Charts were reviewed to determine ICP, cerebral perfusion pressure, mean arterial pressure, serum sodium values, and serum osmolarity before and after treatment with 23.4% sodium chloride and mannitol. Complications were noted. RESULTS: The mean reductions in ICP after treatment were significant for both mannitol (PϽ0.001) and hypertonic saline (PϽ0.001); there were no significant differences between reductions in ICP when comparing the two agents (P ϭ 0.174). The ICP reduction observed for hypertonic saline was durable, and its mean duration of effect (96 min) was significantly longer than that of mannitol treatment (59 min) (P ϭ 0.016). No complications were associated with treatment with hypertonic saline. CONCLUSION: This study suggests that 23.4% hypertonic saline is a safe and effective treatment for elevated ICP in patients after traumatic brain injury. These results warrant a rigorous evaluation of its efficacy as compared to mannitol in a prospective randomized controlled trial.
T raumatic brain injury (TBI) is a major health problem affecting nearly 1,500,000 people in the United States each year (23) . Many patients who sustain TBI have cerebral edema or space-occupying hematomas that produce intracranial hypertension. Conventional medical treatment of intracranial hypertension includes osmotic therapy, hyperventilation, head elevation, and barbiturates, but because other treatments have limited efficacy, mannitol is the mainstay of medical treatment for acute intracranial hypertension. Although mannitol frequently is effective in reducing intracranial pressure (ICP), multiple administrations introduce a risk of kidney failure and mannitol accumulation in brain parenchyma with consequent worsening of cerebral edema (14) . Mannitol works as a systemic diuretic and, under certain circumstances, may contribute to systemic hypotension (5) . Thus, mannitol may be contraindicated for patients who are hypotensive or who are undergoing fluid resuscitation.
Experimental data (2, 28, 34, 40) and clinical studies (10, 39) have shown that hypertonic saline may decrease ICP. Hypertonic saline has also been shown to have beneficial hemodynamic, vasoregulatory, and immunomodulatory effects (9, 12, 31, 32) . Furthermore, treatment with hypertonic saline may increase serum sodium, which has been correlated with improved control of ICP (15, 24, 25, 31) . In a recent study (36) , 7.5% saline was an effective and safe initial treatment for posttraumatic intracranial hypertension refractory to sedation and optimal management of fluids. Furthermore, a recent preliminary case series showed significant decreases in ICP in patients with intracranial hypertension after the intravenous administration of a 23.4% saline solution over 15 to 20 minutes (33) . However, only one of the eight patients in that study had experienced TBI.
There are no conclusive clinical data on the safety and efficacy of higher concentrations of hypertonic saline used to control intracranial hypertension in patients with TBI. We have used 23.4% sodium chloride at our institution to treat a number of patients who had increased ICP after TBI. We chose 23.4% saline because it is the highest concentration of saline available, and it provides the highest osmotic load with a low fluid volume compared with other sodium chloride preparations. In addition, preservative-free 23.4% saline is commercially available and requires no special preparation before injection. In this study, hypertonic saline was used to treat a selected population of patients with TBI who had become tolerant to mannitol.
PATIENTS AND METHODS

Selection of Patients
Between January and October 2003, 141 patients with severe TBI resulting in lesions that caused intracranial hypertension were admitted to San Francisco General Hospital (SFGH). All patients were treated by a multidisciplinary team whose aim was to reduce secondary brain injury. From among those 141 patients, patients who met the following criteria were selected for this retrospective study: 1) treatment with 23.4% sodium chloride solution as described below; 2) age of 18 years or older; 3) injury within 12 hours before admission; 4) patients requiring monitoring of ICP because of a Glasgow Coma Scale (GCS) score lower than 8 at some point during their hospital course or patients requiring postoperative monitoring of ICP; 5) computed tomographic (CT) scan of the brain showing a mass lesion, including epidural hematoma, subdural hematoma, intracerebral or intracerebellar hematoma, subarachnoid hemorrhage with swelling or parenchymal insult, parenchymal contusions, diffuse axonal injury, diffuse swelling with midline shift of more than 2 mm, or depressed cranial fracture; and 6) patients with ICP that could not be adequately controlled with mannitol.
Management
The patients were initially treated in the emergency department, where they received fluid resuscitation and neurological evaluation. Patients who had a GCS score less than 8 received an endotracheal tube. All patients then underwent a CT scan of the head. Patients with subdural or epidural hematomas with mass effect were taken to the operating room immediately for evacuation of the hematoma; those patients had ICP monitors placed postoperatively in the operating room. Patients without mass lesions and a GCS less than 8 were taken directly to the intensive care unit and ICP monitors were placed. Patients admitted with a GCS score greater than 8 who experienced neurological deterioration also had placement of an endotracheal tube and an ICP monitor in the intensive care unit.
The goal of ICP management was to maintain ICP of less than 20 mm Hg. Fluid boluses and vasopressors were used to support blood pressure to maintain a cerebral perfusion pressure Ͼ60 mm Hg. Patients with endotracheal tubes were mechanically ventilated to keep their arterial oxygen pressure (PaO 2 ) above 90 mm Hg and arterial carbon dioxide pressure (PaCO 2 ) between 35 and 40 mm Hg; a central venous catheter was placed in each of those patients. Fluid boluses were used to maintain central venous pressure above 8 cmH 2 0.
Serum sodium values and serum osmolarity were monitored daily and before treatment with either mannitol or 23.4% sodium chloride solution. The target serum sodium value was 140 mEq/L. Patients with serum sodium values less than 135 mEq/L were treated with supplemental enteral sodium chloride. If the serum sodium value continued to decrease despite supplementation, 3% sodium chloride was administered intravenously. Patients with serum sodium values greater than 155 mEq/L were not treated with 23.4% sodium chloride because of the possibility of worsening hypernatremia.
When ICP exceeded 20 mm Hg for more than 5 minutes, patients were evaluated for such causes of increased ICP as poor positioning, agitation, hypoventilation, or noxious stimuli. If necessary, adjustments were made in ventilation parameters or in sedation. If these adjustments were not adequate, cerebrospinal fluid was drained to control ICP in patients who had ventriculostomies in place. If ICP remained high despite these measures, patients received boluses of mannitol in doses determined by the treating physician (0.25-1.9 g/kg). When mannitol did not decrease ICP to under 20 mm Hg for more than 60 minutes, the patient was considered to have developed tolerance to mannitol. Patients then received 30 ml of a 23.4% sodium chloride solution (234 mg/ml, 8008 mOsm/L solution; American Regent Laboratories, Inc., Shirley, NY) intravenously by an SFGH neurosurgeon over a 2-minute period. Two patients were given hypertonic saline because they were undergoing active fluid resuscitation for low central venous pressures while their ICPs were increasing.
After the administration of 23.4% saline for an episode of refractory intracranial hypertension, patients were eligible to receive either hypertonic saline or mannitol for episodes of intracranial hypertension at the discretion of the medical team. In some cases, mannitol and hypertonic saline were given in fairly rapid succession (less than 1 hour apart) for episodes of intractable intracranial hypertension. For these patients, independent administrations for each such episode were excluded from the study because of the complexity of dual treatment.
Chart Review and Comparisons
We retrospectively reviewed the charts of patients eligible for the study to determine ICP, cerebral perfusion pressure, mean arterial pressure, serum sodium values, and serum os-molarity in the hours before and after treatment with 23.4% sodium chloride and mannitol. The duration of ICP reduction was noted. Complications were also noted. This study compared each patient's responses to independent administrations of 23.4% saline with the same patient's responses to independent administrations of mannitol.
Statistical Analysis
For patients with several treatments of mannitol or hypertonic saline, values were averaged such that each patient contributed equally to the overall means. Means and standard deviations (SD) for these values were computed and compared using SPSS for Windows (version 11.5.0; SPSS, Inc., Chicago, IL). Pretreatment values were compared to ensure that there were no statistical differences in these values before treatment with hypertonic saline or with mannitol. Means for each value before and after treatment were also compared to determine whether treatment with either hypertonic saline or mannitol had a statistically significant effect. The paired t test was used to compare all means; the level of significance was set at P Ͻ 0.05.
RESULTS
Patients' Demographic and Diagnostic Characteristics
Of the 141 patients with severe TBI admitted to the Neurosurgery Service at SFGH between January and October 2003, 13 adult (Ն18 yr) patients were eligible according to the inclusion criteria and were included in this study. The patients (10 male, 3 female) ranged in age from 19 to 65 years (mean, 42 yr; median, 37 yr; SD, 15 yr) ( Table 1 ). The mechanisms of injury were as follows: one motor vehicle accident, three motorcycle accidents, three pedestrian-versus-automobile accidents, two falls, one single gunshot wound to the head, and two assaults with a blunt object. One patient had an unknown mechanism of injury. On their arrival in the emergency department, there were three patients with mild head injury (GCS score Ͼ12), three patients with moderate head injury (GCS score 9-12), and seven patients with severe head injury (GCS score Ͻ9). The mean GCS score on arrival was 7.7 (median, 7.0; SD, 4.1). The mass lesions observed on initial CT scans included cerebral contusions in seven patients (54%), subdural hematoma (SDH) in nine (69%) patients, and epidural hematoma (EDH) in two (15%) patients.
Patient Treatment and Outcomes
All patients had an ICP monitor placed shortly after admission ( Table 2 ). Of patients with mild and moderate head injuries, all had clinical deterioration (Patients 10 and 13 required surgery) and ICP monitors in all cases. Of the 13 patients in this study, 3 (23%) received a Camino bolt monitor (Integra LifeSciences Corp., Plainsboro, NJ), and 10 (77%) received a ventriculostomy. Of the 13 patients, 7 had brain-tissue oxygen monitors placed during their hospital course because of their enrollment in another study. Those patients had ICP measurements recorded every minute for the period that the device was in place. Patients without brain tissue oxygen monitors had ICP measurements recorded every 15 minutes. Eight (64%) patients underwent a decompressive craniectomy shortly after admission. One patient (Patient 9) underwent craniectomy for neurological decline associated with the evolution and swelling of a bifrontal contusion 2 weeks after his initial trauma. Of the 13 patients in the study, 3 (23%) were discharged with moderate disability after an average hospital stay of 14 days ( Table 2 ). Four (31%) patients were discharged with severe disability after an average hospital stay of 26 days. Two (15%) patients were discharged in a vegetative state after an average hospital stay of 28 days. Four (31%) patients died while in the hospital after an average hospital stay of 3 days. At the long-term follow-up evaluations, four (31%) patients had upper moderate disability, and one (8%) patient had lower moderate disability on the Glasgow Outcome Scale. Four (31%) patients were lost to follow-up review.
Effects of Mannitol
There were 19 treatments with mannitol among the 13 patients ( Table 3 ). The average dose of mannitol given was 75 g (median, 75 g) or 0.86 g/kg (median, 0.79 g/kg). The average ICP peak for which mannitol was given was 38 mm Hg (median, 39 mm Hg). The average reduction in ICP after mannitol administration was 20 mm Hg (median, 23 mm Hg). A comparison of ICP before and after the administration of mannitol showed that the effect of this treatment was significant (P Ͻ 0.001). In 16 of 19 treatments (84%), there was at least a 25% reduction in ICP, and in 13 of 19 treatments (68%), there was at least a 50% reduction in ICP. The average duration of the effect of mannitol in this population was 59 minutes (median, 74 min).
Effects of Hypertonic Saline
There were 22 treatments with 23.4% saline solution in the 13 patients ( Table 4 ). The average ICP peak for which 23.4% saline was given was 36 mm Hg (median, 29 mm Hg). The average reduction in ICP after hypertonic saline administration was 15 mm Hg (median, 13 mm Hg); this reduction was highly significant (P Ͻ 0.001). There was not a significant difference between ICP reduction after hypertonic saline compared with mannitol (P ϭ 0.174) ( Table 5 ). In 17 of 22 treatments (77%), there was at least a 25% decrease in ICP, and in 12 of 22 treatments (54%), there was at least a 50% reduction in ICP. The average duration of effect of hypertonic saline in this population was 96 minutes (median duration 90 min). The difference between the mean durations of effect of hypertonic saline (96 min) and mannitol (59 min) was profound and statistically significant (P ϭ 0.016). There were two patients (Patients 4 and 9) who had transient reductions in ICP that lasted less than 5 minutes; this very brief duration was deemed Љno effect.Љ Both of these patients subsequently died from high ICP and consequent brainstem dysfunction. There was a trend toward shorter duration of effect for hypertonic saline in severely injured patients with a GCS score of less than 9 when admitted (Patients 1, 4, 5, 9, 11, and 12) compared with less severely injured patients.
Other Effects of Treatment
There were no complications associated with treatment with hypertonic saline. The average serum sodium value was 140 mmol/L before the use of hypertonic saline and 145 mmol/L after treatment. The average serum sodium value was 141 mmol/L before mannitol treatment, and there was a slight increase to 142 mmol/L after treatment. The increase in sodium after the administration of 23.4% saline was statistically significant, and the increase after mannitol treatment was not (P Ͻ 0.001 and 0.174, respectively). The average serum osmolarity before hypertonic saline administration was 312 mmol/kg within 6 hours of treatment and 310 mmol/kg within 4 to 24 hours after treatment (data not shown). The average blood urea nitrogen was 9 mmol/L both before and after administration of hypertonic saline. The average serum creatinine level was 0.8 mmol/L before hypertonic saline administration and 0.7 mmol/L afterward; no patient experienced acute renal failure as a result of hypertonic saline administration. There was one patient with a serum creatinine value of 1.4 before treatment with hypertonic saline that remained unchanged after treatment. There were no episodes of acute anemia or hypokalemia associated with 23.4% saline administration, nor were there any episodes of convulsions, congestive heart failure, or coagulopathy after the administration of hypertonic saline.
DISCUSSION
Much of the effort expended in the care of patients with TBI is to reduce secondary injury. The two most important forms of secondary injury that can be monitored, anticipated, and treated in the intensive care unit are cerebral ischemia and intracranial hypertension (26) . As hypotension occurs in roughly 30% of patients with severe TBI and has been shown to increase mortality rates (6, 37) , proper resuscitation and avoiding hypotension are extremely important measures. The association between intracranial hypertension and poor outcome after head injury has also been well documented (4, 11, 13, 17, 21) . In a recent study, an ICP Ͼ20 mm Hg was a strong predictor of relative risk for neurological deterioration and an eventually poor outcome (13) . Thus, increased ICP can exacerbate the initial injury sustained in TBI and lead to grave disability or death. There is substantial evidence that hypertonic saline at lower concentrations has desirable effects on patients' hemodynamics. The rapid infusion of a small volume of hypertonic solution was originally designed for the prehospital treatment of hemorrhagic shock (3, 8, 16, 18, 22, 35) . The rapid infusion of hypertonic solution leads to an osmotic gradient that draws water into the intravascular compartment with a rapid mobilization of parenchymal fluid (22, 35) . This fluid shift results in hemodilution, endothelial shrinkage, and improved microvascular flow (19, 20) . Additionally, resuscitation with a smallvolume hypertonic solution has been shown to increase cardiac output (3, 8, 18) . The improved cardiac output and reduced microcirculatory resistance combine to improve blood flow through capillary beds and thus lead to metabolic improvement. Because higher cardiac output is likely to protect against hypotension while patients are undergoing fluid resuscitation, the effects of hypertonic saline may be desirable for many patients after TBI.
Hypertonic saline administration has been shown to decrease ICP in a number of animal models (1, 28, 29, 40) . Thus, one might expect hypertonic saline to work well in the hospital setting by both reducing intracranial pressure and improving blood flow to the rich capillary beds within the brain parenchyma. One randomized controlled clinical trial of 1.6% hypertonic saline versus lactated Ringer's solution administration during fluid resuscitation in patients with TBI showed no significant difference in ICP (30); however, methodological issues make this finding difficult to interpret. For instance, the patients' GCS score when admitted was lower, the grade of head injury determined by CT scanning was higher, and the mean and maximal ICP values were significantly higher for the group receiving hypertonic saline at the time they entered the study. Moreover, Cooper et al. (7) showed in a doubleblind, randomized, controlled trial of 229 patients with TBI who were comatose and hypotensive that, in patients treated with prehospital fluid resuscitation using 250 ml of 7.5% saline, there was a trend toward decreased ICPs at admission compared with patients treated with 250 ml lactated Ringer's solutions (10 versus 15 mm Hg, P ϭ 0.08). However, the GOS scores, Functional Independence Measure, and rates of patients returning to work were not statistically different between the two treatment groups. In contrast, a prospective randomized study by Vialet et al. (36) showed that a 7.5% hypertonic saline solution given as a 2 ml/kg bolus was more effective in treating intracranial hypertension than was 20% mannitol given as a 2 ml/kg bolus to posttraumatic headinjured patients with intracranial hypertension that was refractory to sedation, cerebrospinal fluid drainage, and hyperventilation. This study and others (10, 39) suggest that hypertonic saline administration may be useful in the treatment of intracranial hypertension. We describe the use of 23.4% hypertonic saline solution in the treatment of increased ICP in a small group of patients who sustained TBI. Considering the promising results shown with lower concentrations of hypertonic saline, we anticipated that this group would have some reduction in ICP. We limited use of this solution to patients with uncontrolled ICP and required that a physician from the SFGH Neurosurgery team administer the treatment because of the potential risks. The potential risks that have been established experimentally for hypertonic saline administration include hypernatremia, hyperosmolarity, renal failure, convulsions, coma, central pontine myelinolysis, congestive heart failure, hypokalemia, hemolysis, and problems with coagulation (27, 38) . The patients in this study had none of these complications. We found that 23.4% saline could be administered safely while producing a marked reduction in ICP in the patients treated. In most of those patients, the decrease in ICP was sustained for well over an hour. The mean duration of effect of hypertonic saline (96 min) was significantly greater than that of mannitol (59 min).
It is widely believed that the mechanism of action of both hypertonic saline and mannitol in reducing ICP is their hyperosmolar properties. In this study, 240 mOsm of 23.4% saline solution (30 ml of an 8008-mOsm/L solution) was infused over 2 minutes; for mannitol, an average of 497 mOsm (75 g mannitol or 375 ml of 20% mannitol at 1372 mOsm/L) was infused over 30 to 45 minutes. The number of osmoles of hypertonic saline administered was less than that of mannitol in this study. The profound effects of 23.4% saline in rapidly reducing ICP can likely be attributed to its rapid infusion. Another interesting finding in this study was the duration of the effect of 23.4% saline treatment. Increases in serum sodium can lead to better control of ICP in patients with intracranial hypertension (15, 24, 25, 31) . Therefore, it is arguable that the increase in serum sodium in this population may have contributed to better ICP control after the treatment with hypertonic saline. If the increase in serum sodium was the major mechanism acting to reduce ICP, we would have expected more profound changes in ICP in patients with lower sodium levels before treatment with hypertonic saline and smaller changes in patients with higher serum sodium levels before treatment. However, we observed substantial ICP reductions in six of the seven (86%) patients after hypertonic saline treatment who had serum sodium levels of more than 150 mmol/L before treatment. Together, these finding suggest that there may be multiple mechanisms that contribute to the sustained decrease in ICP seen after treatment with 23.4% saline.
In addition, there was an intriguing trend toward shorter duration of effect for hypertonic saline in severely injured patients with a GCS score under 9 at admission (Patients 1, 4, 5, 9, 11, and 12) compared with less severely injured patients. This effect may be related to the severity of injury or to changes in intracranial compliance in this patient population. The explanation for this trend is not clear. This study does not have the power to address this issue, and we suggest a larger trial designed with the statistical power to detect such stratification in effect.
Because of the small number of subjects and treatments in this study, only a few conclusions can be made. There was a profound reduction of ICP in most of the patients with intracranial hypertension treated with hypertonic saline or with mannitol. Because there are some similarities between the mechanisms of action of these two agents, it is likely either intervention would be effective that for many patients with increased ICP. There are theoretical differences, however, that may make hypertonic saline a more favorable treatment under some circumstances. For patients undergoing fluid resuscitation, we would expect that the hemodynamic effects of hypertonic saline would act to reduce ICP while supporting blood pressure. Thus, hypertonic saline may be a better choice when intravascular fluid expansion is desired. Although we found no significant difference in patients' mean arterial pressures after the administration of either 23.4% saline or mannitol, these selected patients had high therapeutic intensities, and closer evaluation of fluid status would be required to see these changes.
In some patients who sustain TBI, 23.4% saline is both safe and effective in the treatment of intracranial hypertension. Based on the results of this preliminary study, we suggest that a large prospective randomized controlled trial be performed to document the effect of hypertonic saline at different concentrations in the treatment of intracranial hypertension in patients who sustain TBI. Only from a larger trial can we determine how to use this promising intervention treatment most effectively.
